Sort by
Refine Your Search
-
challenges and opportunities made possible by human-machine collaboration. The Institute provides a framework to design, implement, and scale AI-driven technologies in ways that make a true difference to
-
Whitney (Department of Mechanical and Industrial Engineering) at Northeastern University, who are both core members of the Institute for Experiential Robotics. They will also have an opportunity
-
) to evaluate novel biomarkers for ADRD. Minimum Qualifications - PhD in computer science, engineering, bioinformatics, biomedical data science, or related field - Familiarity with genomic and bioinformatic
-
". The post carries with it the benefit of substantial opportunities for travel and scientific interaction with Warsaw's Chair of Quantum Mathematical Physics, Chair of General Relativity, and with
-
vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. CSL Seqirus
-
-functionally with other expertise areas such as Pharmacovigilance/Safety, Quality, Legal, Regulatory Affairs, Commercial, Clinical Operations, Clinical Development, and Information Technology, to ensure the safe
-
fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust
-
, Commercial, Clinical Operations, Clinical Development, and Information Technology, to ensure the safe, effective, and appropriate use of our therapies. Fellows will gain hands-on experience in Medical
-
of developing novel, potentially curative therapeutics utilizing CRISPR-based technologies. More specifically, we are employing a modular gene editing platform to create diverse in vivo and ex vivo therapeutics